Short answer
Kura Oncology, Inc. (KURA) filed an 8-K current report with the SEC on September 8, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Jennifer Fulk appointed CFO, principal financial officer and principal accounting officer effective September 8, 2026.
Kura Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Jennifer Fulk appointed CFO, principal financial officer and principal accounting officer effective September 8, 2026
- Replaces Troy E. Wilson as principal financial officer and Thomas Doyle as principal accounting officer
- Base salary $550,000 with discretionary bonus eligibility up to 45%
- Equity package includes 450,000-stock option and performance-based RSUs covering 173,438 shares
- Change-in-control protections include 18 months’ salary, 150% target bonus, benefits and full equity acceleration
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kura Oncology, Inc. 8-K filings
Get the next KURA 8-K as it lands
Follow KURA for push alerts, or ask the research agent what this filing means.